Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women MD Pankau, DB Reeves, E Harkins, K Ronen, W Jaoko, K Mandaliya, ... PLoS pathogens 16 (2), e1008286, 2020 | 48 | 2020 |
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering KR Michels, A Sheih, SA Hernandez, AH Brandes, D Parrilla, B Irwin, ... Journal for immunotherapy of cancer 11 (3), 2023 | 25 | 2023 |
Decay of HIV DNA in the reservoir and the impact of short treatment interruption in Kenyan infants MD Pankau, D Wamalwa, S Benki-Nugent, K Tapia, E Ngugi, A Langat, ... Open Forum Infectious Diseases 5 (1), ofx268, 2018 | 17 | 2018 |
Association between cytomegalovirus and Epstein-Barr virus viremia and human immunodeficiency virus DNA levels in the reservoir of Kenyan infants receiving antiretroviral therapy JA Slyker, B Guthrie, M Pankau, K Tapia, D Wamalwa, S Benki-Nugent, ... The Journal of Infectious Diseases 223 (11), 1923-1927, 2021 | 5 | 2021 |
Cytomegalovirus and Epstein-Barr virus viremia are associated with HIV DNA levels in the reservoir of Kenyan infants on antiretroviral therapy JA Slyker, B Guthrie, M Pankau, K Tapia, D Wamalwa, S Benki-Nugent, ... J. Infect. Dis 223 (11), 1923-1927, 2020 | 5 | 2020 |
HIV reservoir size is not increased by short ART interruption in Kenyan infants M Pankau, D Wamalwa, S Benki-Nugent, A Langat, K Tapia, ... Conference on Retroviruses and Opportunistic Infections. Seattle, USA, 2017 | 2 | 2017 |
Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics S O'Hara, T Rowland, R Koning, D Vereide, M Hoffmann, A Yingst, ... Cancer Research 82 (12_Supplement), 547-547, 2022 | | 2022 |
Gene Editing/Gene Therapies: A SYNTHETIC CYTOKINE RECEPTOR PLATFORM FOR PRODUCING CYTOTOXIC INNATE LYMPHOCYTES AS “OFF-THE-SHELF” CANCER THERAPEUTICS D Vereide, S O’Hara, T Rowland, R Koning, M Hoffmann, A Yingst, ... Cytotherapy 24 (5), S40-S41, 2022 | | 2022 |
VivoVec: A Novel Lentiviral-Based In Vivo CAR T Cell Generation Platform with Viral Particle Surface Engineering Incorporating T Cell Activating and Co-Stimulatory Ligands C Nicolai, J Qin, M Pankau, W Wu, E Naibert, G Hamilton, M Chen, ... MOLECULAR THERAPY 30 (4), 417-417, 2022 | | 2022 |
Preclinical Activity and Safety of UB-VV100, A Novel Lentiviral Vector Product Designed for Selective and Effective In Vivo Engineering of Therapeutic Anti-CD19 CART Cells for … AH Brandes, S Geisinger, A Sheih, A Ting, K Michels, SA Hernandez, ... MOLECULAR THERAPY 30 (4), 579-580, 2022 | | 2022 |
UB-VV100, a Novel Platform for In Vivo Engineering of Therapeutic Anti-CD19 CAR T Cells, Shows Effective T Cell Transduction, B Cell Depletion, and Tumor Control in a Humanized … KR Michels, AM Sullivan, CJ Nicolai, SH Lopez, L Beitz, J Whalen, ... MOLECULAR THERAPY 29 (4), 310-310, 2021 | | 2021 |
Dinâmica do reservatório latente do HIV-1 MD Pankau | | 2019 |
Dynamics of the HIV-1 Latent Reservoir MD Pankau | | 2019 |